Trazodone and ed

Author: steelEllie | 2024-10-17 20:08:55

AbstractObjective: Based on findings of previous studies, those men on Methadone Maintenance Therapy (MMT) have a high prevalence of Erectile Dysfunction(ED), related to hypogonadism and depression. We conducted this study to evaluate the efficacy of Trazodone (an antidepressant which can improve sexual function) on this sexual dysfunction. Method: A structured interview was administered by the clinical staff. The interview contained questions about the subjects' socio-demographic characteristics, their drug use and sexual behavior. In addition to the socio-demographic survey, erectile function was assessed using erectile dysfunction (ED) intensity scale. Of the 157 subjects, 95 suffered from ED. The subjects were informed about the study. Then, seventy five patients voluntarily received 50mg of Trazodone for four days, and the dosage was increased to100 mg and maintained for 6 weeks. Fifty five patients who completed the treatment course were assessed by ED questionnaire again at the end of study. Statistical analysis was performed using Stata 8 software. Results: The prevalence of ED was 60.5% in our sample. The mean erectile dysfunction (ED) intensity scale was 12.21, and 16.78 before and after the treatment course respectively. (P0.05); but it had a significant relation with duration of Methadone therapy and Methadone daily dosage. (p

---

ED is a risk marker for systemic CVD. 25,26,64 The relationship between ED and clinical CVD was originally posited based on a shared clinical risk factor model (including hypertension serotinergic agents trazodone, ketanserin and mian-serin with placebo, trazodone was the superior drug for treatment of erectile dysfunction.13 Clinical experience with patients is

---

Trazodone - Mayo Clinic Connect

Trazodone and ed	steelEllie	Trazodone 150 mg tablets - Patient Information Leaflet (PIL) - (emc)
Is trazodone or Benadryl better? - The Environmental Literacy	(4.4 / 1221 reviews)	As with most psychoactive drug toxicities, the treatment for Trazodone toxicity begins at the site of the incident. There is no Trazodone antidote. Therefore, time is the best
Cialis and trazodone Interactions Checker - Drugs.com	(4.7 / 2867 reviews)	It is suggested that trazodone may be helpful in men with this condition, possibly at higher doses and in menWith psychogenic erectile dysfunction. Evidence‐based medicine is an important way of allowing the reader to judge clearly whether a treatment has a place in a particular condition, and to see what faults were present in the various trials of its efficacy. It is often rather

Trazodone 50mg Capsules - Patient Information Leaflet (PIL)

Of the limitations of the review: the heterogeneous populations, small sample sizes, brief duration of the treatment, and methodological limitations of the included studies. In their discussion, the authors correctly advised caution when interpreting the findings of the review, in particular the results from the subgroup analyses on the influence of the type of ED and trazodone dose on the response rates. This was reflected in the appropriately tentative conclusions.Implications of the review for practice and researchPractice: The authors did not state any implications for practice.Research: The authors stated that high-quality RCTs are required to compare trazodone with placebo and other therapies, especially in men with depression and psychogenic ED. They also stated that the outcomes assessed in future studies should include the proportion of successful sexual intercourse attempts, a validated depression scale and adverse events.FundingVeterans Health Administration, Office of Research and Development, Health Services Research and Development Service, Management Decisions and Research Center, Technology Assessment Programme; Veterans Affairs Medical Center (Minneapolis), Center for Chronic Disease Outcomes Research and Cochrane Review Group in Prostate Diseases and Urologic Malignancies.Bibliographic detailsFink H A, Macdonald R, Rutks I R, Wilt T J. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU International 2003; 92(4): 441-446Indexing StatusSubject indexing assigned by NLMMeSHAdult; Aged; Anti-Anxiety Agents /adverse effects /therapeutic use; Antidepressive Agents, Second-Generation /adverse effects /therapeutic use; Erectile Dysfunction /drug therapy /psychology; Humans; Male; Randomized Controlled Trials as Topic; Trazodone /adverse effects /therapeutic use; Treatment OutcomeAccessionNumber12003001958Date bibliographic record published31/12/2004Date abstract record published31/12/2004Record StatusThis is a critical abstract of a systematic review that meets the criteria for inclusion on DARE. Each critical abstract contains a brief summary of the review methods, results and conclusions followed by a detailed critical assessment on the reliability of the review and the conclusions drawn.

Frontiers

Studies combined?The characteristics of the included studies were summarised in the text of the review, while the results of individual trials were tabulated. For studies comparing trazodone monotherapy with placebo, the pooled weighted relative benefit increase (RBI) and 95% confidence intervals (CIs) were calculated using a random-effects model for the outcome 'positive treatment response'. The weighted relative risk increases and their 95% CIs were also estimated using a random-effects model.How were differences between studies investigated?The authors stated that statistical heterogeneity was assessed (using a significance level of PResults of the reviewSix RCTs (n=396) were included.One RCT reported an adequate method of randomisation and allocation concealment. Five RCTs were stated to double-blinded.Efficacy.The two RCTs assessing successful sexual intercourse attempts found that trazodone with and without yohimbine significantly improved the likelihood of successful intercourse in men with psychogenic ED. The RBI was 5.0 (95% CI: 1.7, 15.2) for the RCT comparing trazodone with placebo, and 4.5 (95% CI: 1.5, 13.9) for the RCT comparing trazodone plus yohimbine with placebo.Trazodone monotherapy versus placebo (4 RCTs, 209 men): trazodone increased the likelihood of a positive treatment response compared with placebo, but the increase was not statistically significant. The pooled RBI was 1.6 (95% CI: 0.8, 3.3).The results for treatment response according to type of ED and trazodone dose were also reported in the paper.Adverse events.Not all studies reported withdrawals and adverse effects. There was no significant difference between trazodone and placebo in the proportion of withdrawals for any reason, or for withdrawals due to adverse effects, but the CIs were wide and the authors stated that an increased risk of adverse effects could not be excluded. The RBI was 1.0 (95% CI: 0.4, 2.5) for all withdrawals (4 RCTs) and 2.6 (95% CI: 0.8, 8.6) for withdrawals due to adverse effects (3 RCTs). Data on specific adverse effects were not uniformly reported. There were no statistically significant differences between trazodone and placebo for specific adverse effects. The most common adverse effects in men treated with trazodone were dry mouth (19% versus 11% with placebo), sedation (16% versus 6% with placebo), dizziness (16% versus 0% with placebo) and fatigue (15% versus 8% with placebo).Authors' conclusionsTrazodone may be a helpful treatment for erectile dysfunction, particularly at higher doses and in men with psychogenic ED.CRD commentaryThe review question was clear in terms of the study design, participants, intervention and outcomes. Several relevant sources were searched, the search terms were stated, attempts were made to locate unpublished studies, and no language restrictions were applied. Two reviewers independently selected the studies, assessed validity and extracted the data, which reduces the potential for bias and errors. Validity was assessed using established criteria.Some relevant information on the included studies was tabulated, while additional information was described in the text of the review. The data were combined in a meta-analysis and the authors stated that statistical heterogeneity was assessed. However, the results of the assessment were not reported. The subgroup analyses do not appear to have been pre-specified. The authors discussed some

Based on our findings, it is clear that patient education and counseling needs to be drastically improved prior to starting trazodone. Providing the proper information to patients Using traZODone together with sertraline can increase the risk of a rare but serious condition called the serotonin syndrome, which may include symptoms such as confusion, hallucination